Oculis to Present at the Upcoming Virtual European Biotech Investor Day 2020

23 June, 2020

Oculis Reports Positive Top-line Data from SKYGGN (Phase 2) Trial with OCS-01

18 May, 2020

Oculis Announces Upcoming Presentation of SKYGGN Phase 2 Data at ASCRS

07 May, 2020

Oculis Appoints Dr. Frédéric Pilotaz as VP of Technology & Pharmaceutical Sciences

21 April, 2020

Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer

03 March, 2020

Phase 2 Study Results of OCS-01: A Potential Topical Therapeutic for DME

10 February, 2020

Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME

22 January, 2020

Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial

07 October, 2019

Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board

17 September, 2019